THE LITERATURE LIST:

1. Angeles-han S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis — a case report//J. Rheumatol. — 2008. V. 35, № 9. — P. 1897-1898.

2. Barr S.G., Steber W., Kindopp-Bugo K., Martin O.L. Infliximab therapy in the treatment of rheumatoid arthritis in clinical practice.//Ann. Rhem Dis. - 2003. - 62. - P. 196.

3. Beukelman T., Patkar N.M., Saag K.G., et al. 2011 American College of Rheumatology Recomendations for the Treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features//Arthritis Care Res. (Hoboken). — 2011. — Vol. 63. — P. 465—82.

4. Beutler B.A. The role of tumour necrosis factor in health and disease//J. Rheumatol. - 1999. - 26 (Suppl. 57). - P16—21.

5. Bigbee C. L., Gonchoroff D. G., Vratsanos G. et al. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice//Arthritis Rheum. — 2007. V. 56. — P. 2557-2565.

6. Breda L., Del Torto M., De Sanctis S., Chiarelli F. Biologics in children's autoimmune disorders: efficacy and safety.//Eur J Pediatr. DOI 10.1007/s00431-010-1238-z

7. Bredveld F.C., Emery P., Keystone E., et al. Infliximab in active early rheumatoid arthritis.//Ann Rheum Dis. - 2004. - 63. - P. 149-155.

8. Bristol-Myers Squibb: Summary of product characteristic. 2007. http://www.emea.europa.eu/humandocs/PDFs/EPAR/orencia? H-701-PI-en.pdf.

9. Carrasco R., Smith J.A., Lovell D. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs.-. 2004. 137-146.

10. Cassidi J.T., Petty R.E. Textbook of Pediatric Rheumatology. — Toronto: W.B. Saunders Company, 2011. — P. 211-235.

11. Chaturvedi V.P. Pilot study of chimeric monoclonal anti-tumour necrosis factor alpha anti-body (infliximab) with methotrexate in polyarticular juvenile idiopathic arthritis [abstract].//American College of Rheumatology 66th Annual Scientific Meeting, New Orleans, LA. Abstract LB12.-. October 24 - 25. - 2002.

12. Crandall WV, Mackner LM. Infusion reactions to infliximab in children andadolescents: frequency, outcome and a predictive model.//Aliment Pharmacol Ther. 2003. - 17 (1). - THE RIVER 75-84

13. Davies K., Cleary G., Foster H., et al. BSPAR Standards of care for children with juvenile idiopathic arthritis//J. Rheumatology. — 2010. — Vol. 49. — P. 1406—408.

14. Davies R., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity.//J. Rheumatol. - 2007. - 34. - THE RIVER 280-289.

15. Diak P., Siegel J., Grenade L. Malignancy in children and TNF blockers: forty eight cases reported to the Food and Drug administration.//Arthr. Rheum. - 2010. - 61. - 8. - THE RIVER 2517-2524.

16. Eberhard BA, Ilowite NT. Response of systemic onset juvenile rheumatoid arthritis to etanercept: is the glass half full or half empty?//J Rheumatol. - 2005. - 32 (5). - THE RIVER 763-765.

17. Elliot M.J., Maini R.N., Feldmann M., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis.//Lancet. - 1994.-344. - P.

18. Elliot M.J., Woo P., Charles P., et al. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-a (cA2).//Br J Rheumatol. - 1997. - 36. P. 589-593

19. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F.M., Walker J., Bijl H., Ghrayeb J., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor alpha.//Arthritis Rheum. - 1993. - 36. - P. 1681-90.

20. Emery P., Durez P., Dougados M. et al. Efficacy of abatacept in delaying the development of rheumatoid arthritis (RA) in adult patients with undifferentiated inflammatory arthritis at high risk of developing RA [0P-0130]//Ann. Rheum. Dis. — 2008. V. 67, Suppl II. — P. 89.

21. Emery P., Sebba A., Huizinga T.W. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis.//Ann. Rheum. Dis. - 2013. - 72 (12). - THE RIVER 1897-1904.

22. Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.//J Rheumatol - 2007. - 34 (5). - THE RIVER 1146-50.

23. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.//Ophthalmology - 2006. - 113. (12) - THE RIVER 2317-23.

24. Genant H. K., Peterfy C. G., Westhovens R. et al. Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial//Ann. Rheum. Dis. — 2008. V. 67. — P. 1084-1089.

25. Genovese M. C., Becker J. C., Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumour necrosis factor alpha inhibition//N. Engl. J. Med. — 2005. V. 353. — P. 1114-1123.

26. Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy of repeated intravenous infusions of an anti-tumour necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open­label prospective study.//Arthritis Rheum. - 2005. - 52. - THE RIVER 548-53.

27. V., I., Gattinara M., Fantini F. Focus on adverse events of tumour necrosis factor? blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.//Ann Rheum Dis. - 2008. - 67. - THE RIVER 1145-1152.

28. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A et al. Long-term safety and effectiveness of etanercept in children with selected
categories of juvenile idiopathic arthritis.//Arthritis Rheum. - 2009. - 60. (9) - THE RIVER 2794-804.

29. Haines K.A. Juvenile idiopathic arthritis. Therapies in the 21st Century//Bulletin of the NYU Hospital for Joint Diseases. — 2007. — Vol. 65 (3). — P. 205—11.

30. Hayward K., Wallace C. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis.//Arthr. Res. &Ther. 2009, 11:216 (doi:10.1186/ar2619).

31. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.//Ann Rheum Dis - 2009. - 68. (4) - THE RIVER 519-25.

32. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ et al. The German etanercept registry for treatment of juvenile idiopathic arthritis.//Ann Rheum Dis. - 2004. - Vol. 63 (12). - THE RIVER 1638-44.

33. Horneff G. Treatment options with biologics for juvenile idiopathic arthritis//Int. J. Clin. Rheum. — 2011. — Vol. 6 (3). — P. 1—19.

34. Horneff G. Update on biological for treatment of juvenile idiopathic arthritis.//Exp. Opin. Biol. Ther. - 2013. - Vol. 13 (3). - P. 361-376.

35. Horneff G., De Bock F., I., Girschick H.J., et al. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry.//Ann Rheum Dis published online 15 Apr 2008; doi:10.1136/ard.2007.087593.

36. Horneff G., Ebert A., Fitter S., et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis//Rheumatology - 2009. - 48. - P. 916-919

37. Hugle B., Hinze C., Lainka E., Fischer N., Haas J. Development of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course.//

Pediatric Rheumatology - 2014. - 12:28. - http://WWW.PED -

rheum.com/content/12/1/28.

38. Janneke Anink, Marieke H, Otten, Spronk S., Lisette W.A. Van Suijlekom-Smit, Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands Efficacy of Biologic Agents in Juvenile Idiopathic Arthritis//A Systematic Review Using Indirect Comparisons. - 2013. - P. 1178-1179.

39. Kalden J.R. Emerging role of anti-tumour necrosis factor therapy in rheumatic diseases//Arthritis Res. - 2002. - 4. - P. 534—540.

40. Keane J., Gershon S., Wise R. Tuberculosis associated with infliximab, a tumour necrosis factor a - neutralising agent.//New Engl J Med. - 2001. - 345. - P. 1098-1104.

41. Kietz D.A., Pepmueller P.H., Moore T.L. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis//J Rheumatol. - 2001. - 28. - P. 360-362.

42. Kievit W., Adang E.M., Fransen J. et al. The effectiveness and medication costs of three anti-tumour necrosis factor an agents in the treatment of rheumatoid arthritis from prospective clinical practice data.//Ann. Rhem. Dis. - 2008. - 67. - P. 1229-1234.

43. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis//J Rheumatol. - 2005. - 32. - P. 935-42.

44. Klein A., Hornef G. Treatment strategies for juvenile idiopathic arthritis.//Expert Opin Pharmacother. - 2009. - Vol.10. - 18. - P. 3049-3060.

45. Kremer J. M., Genant H. K., Moreland L. W. et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial//Ann. Intern. Med. - 2006. - 144. - P. 865-876.

46. Kremer J. M., Genant H. K., Moreland L. W. et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate//Arthritis Rheum. — 2008. — Vol. 58. — P. 953­963.

47. Kremer J. M., Westhovens R., Leon M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4lg.//N. Engl. J. Med. - 2003. - 349. - P. 1907-1915.

48. KremerJ. M., Dougados M., Emery P., Durez P., Sibilia J., Shergy W., Steinfeld S., Tindall E., Becker J. C., Li T., I. F., Aranda R., Moreland L. W. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial//Arthritis Rheum. - 2005. - 52. - P. 2263-2271.

49. Lahdenne P., Vahasalo P., V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study//Ann Rheum Dis. - 2003. - 62. - P. 245-247.

50. Lamot. L, Bukovac L.T., Vidovic M., Frleta M., Harjacek M. The “head-to-head” comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis//Clinical and Experimental Rheumatology - 2011. - 29. - P. 131-139.

51. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumour necrosis factor inhibitors cause uveitis? A registry-based study//Arthritis Rheum. - 2007. - Vol. 56 (10). - P. 3248-52.

52. Lim LL. Uveitis following the use of tumour necrosis factor alpha inhibitors: Reply on comments//Arthritis Rheum. - 2008. - 58. - P. 1556-1557.

53. Linsley P S., Brady W., Urnes M., Grosmaire L. S., Damle N. K., Ledbetter J. A. CTLA-4 is a second receptor for the B cell activation antigen B7//J. Exp. Med. - 1991. - 174. - P. 561-569.

54. Lipsky P.E., van der Heijde D.M.F.M, St Clair E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis.//N Engl J Med. - 2000. - 343. - P.1594-1602

55. Lorenz H.M., Kalden J.R. Perspectives for TNFa targeting therapies.//Arthritis Research. - 2002. - 4. - P. 17-24.

56. Lovell D.J. Update on treatment of arthritis in children. New Treatments, new Goals//Bulletin of the NYU Hospital for Joint Diseases. — 2006. — Vol. 64 (1). — P. 72—6.

57. Lovell D.J., Giannini E.H., Reiff A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis.//N. Engl. J. Med. - 2000. - 16. 342 (11). - P. 763-769.

58. Lovell D.J., Giannini E.H., Reiff A., et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial//Arthritis Rheum. — 2003. — Vol. 48. — P. 218—26.

59. Lovell D.J., Giannini E.H., Reiff A., Jones O.Y., Schneider R., Olson J.C., et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open­label, extended-treatment trial//Arthritis Rheum. - 200. - 48. - P. 218-226.

60. Lovell D.J., Reiff A., Ilowite N.T., Wallace C.A. et al. Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with Juvenile rheumatoid arthritis//Arthritis Rheum. - 2008. - 58 (5). - P. 1496-1504.

61. Lovell D.J., Reiff A., Jones O.Y., Schneider R., et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis//Arthritis Rheum. - 2006. - 54. - P. 1987-1994.

62. Maini R., St. Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., Lipsky P. Infliximab (chimeric anti­tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.//Lancet. - 1999. - 4. - P.1932-1939.

63. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiplay intravenous infusion of anti-tumour necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.//Arthritis Rheum. - 1998. - 41. - P. 1552-1563.

64. McDevitt H, Munson S, Ettinger R, Wu A. Multiple roles for tumour necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity//Arthritis Res. - 2002. - 3. - P. 141-152.

65. Milden K., Niewerth M, Zink A. Long-term outcome of patient with JIA treated with etanercept, results of the biologic register//JuMBO. Rheumatology (Oxford). - 2012. - 51 (8). - P.1407-15.

66. Moreland L. W., Alten R., Van den Bosch F. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, doubleblind, placebo-controlled clinical trial evaluating CTLA-4lg and LEA29Y eighty-five days after the first infusion//Arthritis Rheum. - 2002. - 46. - P. 1470-1479.

67. Mourao A.F., Santos M.J., Melo Gomes J.A. Biologic disease modifying FNTI - rheumatic drug use in the treatment of juvenile idiopathic arthritis//data from the rheumatic diseases Portuguese register, REUMA.PT.//10.1136/ANNRHEUMDIS - 2014-eular-5276.

68. Otten M., Prince F., Twilt M. et al. Delaed clinical response in patients with juvenile idiopathic arthritis treated with etanercept//J.Rheumatol. - 2010. - 37. - P. 665-667.

69. Otten M.H., Anink J., Spronk S., van Suijlekom-Smit L.W. Efficacy of biological agent in juvenile idiopathic arthritis: a systematic review using indirect comperisons.//Ann. Rheum. Dis. - 2013. - 72 (11). - P. 1806-1812.

70. Pain C., McCann L. Challenges in the management of juvenile idiopathic arthritis with etanercept//Biologics: Targets &Therapy. - 2009. - 3. - P. 127-139.

71. Petty R.E., Southwood T.R., Manners P., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001//J. Rheumatol. — 2004. — Vol. 31. — P. 390—92.

72. Phelan J.D., S.D.Thompson, D.N.Glass, Susceptibility to JRA/JIA: complementing general autoimmune and arthritis traits//Genes Immun. - 2006. - 7. - P. 1-10.

73. I., V., Gattinara M. Et al. Effect of anti-tumour necrosis factor alpha antibody (infliximab) on chronic uveitis in juvenile idiopathic (chronic) arthritis//Ann. Rheum. Dis. - 2002. - 61. - P. 382.

74. Prince F.H.M., Twilt M., ten Cate R., Van Rossum M.A.J., et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register//Ann Rheum Dis published online 15 Apr 2008 doi:10.1136/ard.2007.087411.

75. Quartier P, Taupin P, Bordeaut F, Lemelle I, Pillet P, Bost M, et al Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type//Arthritis Rheum. - 2003. - 48. - P. 1093-1101.

76. Rabinovic WITH. E Use of Tumor Necrosis Factor Inhibitors in uveitis//Curr Opin Rheumatol. - 2007. - 19 (5). - THE RIVER 482 - 486.

77. Raychaudhuri S.P., Nguen C.T., Raychaudhuri S.K., Gershwin M.E. Incidence and nature of infectious disease in patients treated with anti-TNF agents//Autoimmuniti reviews. - 2009. - P. 67-81.

78. Reddy AR, Backhouse OC. Does etanercept induce uveitis?//Br J Ophthalmol. -

2003. - 87 (7). - P. 925.

79. Ringold S., Weiss P.F., Beukelman T., et al. 2013 Update of the 2011 American College of Rheumatology Recomendations for the Treatment of juvenile idiopathic arthritis. Recomendations for the medical therapy of children with juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications//Arthritis Rheum. — 2013. — Vol. 65 (10). — P. 2499 512.

80. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: Findings from an open-label treatment extension//Ann Rheum Dis. - 2009. [Epub. ahead of print].

81. Ruperto N., Lovell D. J., Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial//Lancet. — 2008. V. 372, № 9636. — P 383-391.

82. Ruperto N., Lovell D.J., Cuttica R. et al./A randomized, placebo - controlled trial of infliximab plus methotrexate for the treatment of polyarticular - course juvenile rheumatoid arthritis//Arthr. Rheum. - 2007. - 9. - P. 3096-106.

83. Russo RA, Katsicas MM, Zelazko M. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol 2002; 20 (5):723-6. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B et al. Etanercept therapy in children with treatment-resistant uveitis//Arthritis Rheum. - 2001. - 44 (6). - P. 1411-1415.

84. Russo RA, Katsicas MM, Zelazko M. Etanercept in systemic juvenile idiopathic arthritis//Clin Exp Rheumatol. - 2002. - 20 (5). - P. 723-726.

85. Schiff M. H., Pritchard C., Huffstutter J. E. et al. The 6-month safety and efficacy

of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial//Ann. Rheum. Dis. — 2009. http://ard.bmj.com/cgi/

rapidpdf/ard.2008.099218v1.

86. Schiff M., Keiserman M., Codding C. et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomised, double­blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate//Ann. Rheum. Dis. — 2008. V. 67. — P. 1096-1103.

87. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). - 2005. - 44 (8). - P. 1008-11.

88. Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol. - 2003. - 15 (4). - P.380-386.

89. Sibilia J., Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis//Clin. Exp. Eheumatol. — 2007. V. 25 — P. 46-56.

90. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis//Arthritis Rheum. - 2005. - 53 (1). - P.18-23.

91. Stevens A., Meyer S., Hanson D., Clayton P., Donn R. Network analysis identifies protein clusters of functional importance in juvenile idiopathic arthritis.//Arthritis Research &Therapy. - 2014. - 16. - P.109.

92. Swart J.F., Sytze de Roock, Wulffraat N.M. What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?//Arthritis Research &THERAPY. - 2013. - 15. - P. 213.

93. Szer I.S., Kimura Y., Malleson P.N., Southwood T.R. Arthritis in children and adolescents: Juvenile idiopathic arthritis//Oxford university press. - 2013. - P.456

94. Takei S, Groh D, Bernstein B, Shaham B, Gallagher K, Reiff A. Safety and effi cacy of high dose etanercept in treatment of juvenile rheumatoid arthritis.//J Rheumatol. - 2001. - 28 (7). - P. 1677-1680.

95. Twilt M., ten Cate R., van Rossum M.A.J., Wulfraat M.M., et al. Long-term follow-up of etanercept in the treatment of juvenile idiopathic arthritis; The Dutch national study//Ann Rheum Dis. - 2006. - 65. - P. 572.

96. Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, V. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis//Ann Rheum Dis. - 2006. - 65 (8). - P. 1044-1049.

97. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis//Ann Rheum Dis. - 2007. - 66 (4). - P. 548-550.

98. U.S.Food and Drug Administration. Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). CDER Homepage. http://www.fda.gov/cder/drug/early_comm/TNF_blockers.htm2008. (41)

99. U.S.Food and Drug Administration. Follow-up to the June 4, 2008 Early

Communication about the Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). http://www. fda.gov/Drugs/DrugSafety/PostmarketDrug
SafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcarePr ofessionals/ucm174449.htm 2009.

100. Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy//Arthritis Rheum. - 2002.-46. - P. 755-765.

101. Vis M., Wolbink J., Soesbergen R., et al. Early changes in bone metabolism in patients with rheumatoid arthritis treated with infliximab.//Ann Rheum Dis. - 2002. - 61. - P. 51.

102. Vojvodich PF, Hansen JB, Andersson U, Savendahl L, Hagelberg S. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis//J Rheumatol. - 2007. - 34 (12). - P. 2481-2485.

103. Wahezi D.M., Ilowite N.T. Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.//Exp. Opin. Pharmacoter. 2013; 14 (8: 975-989/) (156)

104. Wallace C.A. Developing standards of care for patients with juvenile idiopathic arthritis//J. Rheumatology. — 2010. — Vol. 49. — P. 1213—14. (81)

105. Wallace C.A., Ruperto N., Gannini E. et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis//J. Rheumatol. -

2004. - 31 (11). - P. 2290-2294.

106. Webb L. M., Walmsley M. J., Feldman M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2//Eur. J. Immunol. - 1996. - 26. - P. 2320­2328.

107. Weinblatt M., Combe B., Covucci A. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: an one-year randomized, placebo-controlled study//Arthritis Rheum. — 2006. V. 54. — P. 2807-2816.

108. Weinblatt M., Schiff M., Goldman A. et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial//Ann. Rheum. Dis. — 2007. V. 66. — P 228-234.

109. Weisman M. H., Durez P, Hallegua D. et al. Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis//J. Rheumatol. — 2006. V. 33. — P. 2162-2166.

110. Westhovens R. Robles M., Ximenes A. D. et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors//Ann. Rheum. Dis. — 2009. Well on: http://ard.bmj.com/cgi/rapidpdf/ard. - 2008. - 101121v1.

111. Westhovens R., Kremer J., Moreland L. et al. Durable impact on disease activity and consistent safety through 5 years in abatacept-treated RA patients background methotrexate [FRI0171]//Ann. Rheum. Dis. — 2008. V. 67, Suppl II. — P 341.

112. Wilkinson N., Jackson G., Gardner-Medwin J. Biologic therapies for juvenile arthritis//Arch Dis Child. - 2003. - 88. - P. 186-191.

113. Alekseeva A.M.efficiency and safety of a blocker the TNF-ALPHA - infliksimaba at patients juvenilnym a pseudorheumatism//the Autoref. Diss.... kand.med.nauk - M - 2008. - C.23.

114. Alekseeva Rams, the Management on biological therapy. - M. - 2011.

115. Alekseeva E.I., Bzarova T.M., Tsurikova N.A., Denisov R.V.Rezultaty opened, spent to one centre, nerandomizirovannogo, without group of comparison, observant research of an estimation of quality of a life at patients with juvenilnym the idiopathic arthritis, treated etanertseptom in a combination with metotreksatom.//Questions of modern pediatrics. - 2011. - №6. - C.26-34.

116. Alekseeva E.I., Valieva S.I., Bzarova T.M., Denisov R. V, Isaeva K.B., Sleptsova T.V., Mitenko E.V., Tajbulatov N.I.result of open clinical research of IV phase on studying of efficiency and
Safety abatatsepta at children and teenagers with polyarticulary juvenilnym an idiopathic arthritis without system implications in Russia.//Questions of modern pediatrics. - 2013. - N 4. - S.64-72.

117. Alekseeva E.I., Litvitsky P.F.Juvenilnyj a pseudorheumatism: an aetiology, a pathogenesis, clinic, algorithms of diagnostics and treatment: / the Management for doctors, teachers, scientific employees//Under A.A.Baranova's general edition. - M - CONDUCT, 2007. - C. 368.

118. Amirdzhanova V. N, Nasonov E.L.Abatatsept and quality of a life sick of a pseudorheumatism (results of the international researches)//Scientifically-practical rheumatology. - 2010. - 4 (2). - C. 32-35.

119. Baranov A.A., Alekseeva E.I.clinical of the reference for pediatrists. Children's rheumatology. JUvenilnyj an arthritis, M, - 2013. — С.117.

120. Baranov A.A., Alekseeva E.I., Valieva S.I., Bzarova T.M. and co-authors Therapy by genno-engineering biological preparations: efficiency and safety perekljuchenija.//Questions of modern pediatrics. - 2014. - 13. - №1. - S.33-48.

121. Bzarova T. M, Alekseeva E. I, Fetisova A. N, Klochkova O. A. Application experience abatatsepta at sick of a seropositive variant idiopathic juvenilnogo an arthritis//Questions of modern pediatrics. - 2012. - 2. - with. 155-162.

122. Bzarova T.M., Alekseeva E.I., Fetisova A.N., TSurikova N.A.place of soluble receptors the TNF-ALPHA in treatment juvenilnogo an idiopathic arthritis.//Questions of modern pediatrics. - 2012. - №4. - with. 29-37.

123. Vahljarskaja S.S., Kondratenko I.V., Bologov A.A.Infliksimab in therapy of serious forms juvenilnogo a pseudorheumatism at detej.//Pediatrics. - 2008. - 87. № 2. - with. 98-100.

124. Galstjan L.A., Zholobova E.S., Rozvadovsky Island S, Bunin A.V., Starikova A.V.efficiency adalimumaba at the patient with juvenilnym
Idiopathic arthritis and uveitis//Questions of modern pediatrics. - 2012. - N 6. - S.142-146.

125. Geppe N.A., Podchernjaeva N.S., Lyskina G. A. A management on children's rheumatology, Moscow, "GEOTAR-MEDIA", - 2011. - With. 162-176.

126. Gorjajnov S.V., Avksenteva M. V, Omeljanovsky V.V. Klinicheskaja efficiency of biological preparations at juvenilnom a pseudorheumatism: indirect sravnenie.//Medical technologies. An estimation and a choice. — 2011. — N 4. — with. 9-16.

127. Denisov R. V, Alekseeva E.I.international application experience abatatsepta for treatment of a refractory uveitis at patients with juvenilnym an idiopathic arthritis//Questions of modern pediatrics. - 2011. - №5. - 10. - with. 39-44.

128. Dubko M. F, Kalashnikov O. V, Kostik M. M, Masalova V.V., the Snegiryov of h.p. application Experience abatatsepta at patients and juvenilnym an idiopathic arthritis//Scientifically-practical rheumatology. - 2012. - 54. - with. 106-109.

129. ZHolobova E.S.role hereditary (immunologic) and sredovyh (infectious) factors in development juvenilnyh arthritises: an autoref. dis.

... d.m.n.: 14.01.08 / Zholobova Elena Spartakovna. - M, 2005. - 6с.

130. Zholobova E.S., Nikolaev of M. N, Suhoveva O.G.Effektivnost infliksimaba at the patient with the system form juvenilnogo a pseudorheumatism//Questions of modern pediatrics. - 2011. - N 2. - with. 201-204.

131. Zholobova E.S., Chebysheva S.N., Meleshkina A.V.differential diagnostics of an articulate syndrome at juvenilnyh artritah.//the Attending physician. - 2013. - N 6. - with. 10-14.

132. Zholobova E.S., Shahbazjan I.E., Ulybina O. V, Afonin E.JU.management on children's rheumatology / under the editorship of N.A.Geppe, N.S.podchernjaevoj, G.A.Lyskinoj. M: GEOTAR-MEDIA, 2011. - With. 162-245.

133. ZHolobova E.S.reactive an arthritis. Cardiology and rheumatology of children's age. / under G.A.Samsyginoj's edition - M - Medical practice M - 2004.

- S.601-621.

134. Keltsev V. A, Grebenkina L.I., Prjanichnikova N.S., Gorjunov S.A., Lagoda N.V.efficiency and safety abatatsepta in a combination with Methotrexatum and monotherapies by Methotrexatum at patients with polyarticulary varianom juvenilnogo an idiopathic arthritis.//Questions of modern pediatrics. - 2012. - 11 (6). - S.103-109.

135. Kozlova A.L.efficiency and safety himernyh monoclonal antibodies to ФНО-a at juvenilnom ankylosing spondilitite: dis.... kand.med.nauk: 14.01.08/Kozlova Anna Leonidovna. - M, 2001. - 24 with.

136. Malievsky V.A.Kachestvo of a life of patients with juvenilnym idiopathic artritom.//Questions of modern pediatrics. - 2006. - 5. - with. 152.

137. Malievsky V.A.Territorialnyj the register of patients with juvenilnymi arthritises//Scientifically-practical rheumatology. - 2005. - 4. - S.95-97.

138. Malievsky Century A, Gareyev G. R, Alekseeva E.I.clinico the analysis of efficiency of application etanertsepta at sick juvenilnym rhematoid artritom.//Questions of modern pediatrics. - 2012. - 1. - S.177-181.

139. Malievsky Century A, Gareyev G. R, Prolygina D.D., Pervushina E.P., Nuriahmetova A.Z., JAlaeva L.F.experience of application infliksimaba at juvenilnyh arthritises in republic Bashkortostan.//Questions modern pediartii. - 2012. - 11 (6). - S.125-130.

140. Meleshkina A. V, Eljashevich V. JA, Mikhalev G. V, Zholobova E. S, Geppe N. A, Rozvadovsky Island S, Chebysheva S. N. Clinicoradiological dynamics at the patient with the system form juvenilnogo a pseudorheumatism on therapy etanertseptom.//the Attending physician. - 2011. - 4. - S.12-16.

141. Meleshkina A.V., Chebysheva S.N., Zholobova E.S., Burdaev N.I.feature of an articulate syndrome at different forms juvenilnyh arthritises//Consilium medicum. Pediatrics. - 2013. - 3. - S.80-84.

142. Mihels H, Nikishina I.P., Fedorov E.S., Salugina S.O.GennoYoinzhenernaja biological therapy juvenilnogo an arthritis.//Nauchnoyopraktichesky rheumatology. - 2001. - 1. - С.32 - 34.

143. Mihels H, Nikishina I.P., Fedorov E.S., Salugina S.O.GennoYoinzhenernaja biological therapy juvenilnogo artrita.//Nauchnoyopraktichesky rheumatology. - 2011. - №1. - with. 78-91.

144. Nasonov E.L.Novye aspects of pharmacotherapy of a pseudorheumatism — blockade kostimuljatsii T limfotsitov.//RMZH. - 2009. - 17 (3). - С.2 - 7.

145. Nasonov E. L, Karateev D. E. Application of a blocker of bone-muljatsii T of lymphocytes abatatsepta at rhematoid artrite.//Scientifically-practical rheumatology. - 2010. - 4 (2). - С.9 - 27.

146. Nasonov E.L.clinical of the reference. Rheumatology. 2 izd. M - 2010. — With. 231-70.

147. Nasonov E.L., Nasonov V. A. Rheumatology: the National management. M: GEOTAR-MEDIA, 2008. - With. 720.

148. Neroev V.V., Katargina L.A., Denisova E.V., Starikova A.V., Ljubimova N.V.efficiency of genno-engineering biological preparations in treatment of uveites, assotsiirovannyh with rheumatic diseases at detej.//Scientifically-practical rheumatology. - 2012. - 4 (53). - С.91 - 95.

149. Nikishin I.P. Application abatatsepta in treatment juvenilnogo an arthritis. Scientifically-practical rheumatology. - 2010. - 4 (2). - with. 42 - 45.

150. Nikishin I.P.soluble receptors to the factor of a necrosis of a tumour (etanertsept) in therapy juvenilnogo artrita.//the Russian medical magazine. - 2009. - 3. - with. 177-182.

151. Nikishin I.P.Etanertsept in treatment juvenilnogo an arthritis: from experience of clinical researches to clinical praktiki.//Russian medical magazine. - 2010. - 27. - with. 1686.

152. Nikishina I.P., Malievsky Century A, Fedorov E.S., Pervushina E.P.Nuriahmetova A.ZH.experience of application abatatsepta at sick juvenilnym
Pseudorheumatism with a secondary inefficiency infliksimaba.//Questions of modern pediatrics. - 2011. - 10 (3). - with. 170 - 174.

153. Nikishina I.P., Rodionovsky With.

154. Nikishina I.P., Rodionovsky S.R.Methotrexatum at therapy juvenilnogo an arthritis. The/grant for doctors. - Moscow. - 2006. - with. 148.

155. Nikishina I.P., S.V.Arsenyev, D.L.Alexey, A.V.Smirnov Pautsiartikuljarnyj a youthful arthritis with ANF - assotsiirovannym a uveitis: clinical observation of a family case at mother and the daughter with an outcome in an ankylosing spondylitis at mother//Pediatric pharmacology. - 2014. - 11 (1). - with. 44-50.

156. Nikishina I.P., Fedorov E.S., Alekseev D.L., Rodionovskaja S.R., SHapovalenko A.N.Infliksimab in therapy of refractory variants juvenilnogo an arthritis//Questions of modern pediatrics. - 2010. - 1. - with. 142 - 149.

157. Rohlina F.V., Novik G. A «the Gold standard» in treatment juvenilnogo idiopathic artrita.//the Attending physician. - 2013. - 3. - with. 4.

158. Sleptsova T.V. the author's abstract kmn Efficiency and safety of an inhibitor the TNF-ALPHA - infliksimaba at early juvenilnom a pseudorheumatism.: the dissertation... The candidate of medical sciences: 14.01.08 / Sleptsova Tatyana Vladimirovna; - Moscow, 2011.160 with.

159. Tepikina E.N., the Comparative analysis of efficiency of modern methods of treatment juvenilnyh idiopathic arthritises at children and teenagers//Scientific sheets. A series Medicine. Pharmacy. - 2011. - 10.

- С.87 - 92.

160. Tereshchenko A. Juvenilnyj an arthritis: modern references on diagnostics and lecheniju.//Rheumatology - the Congress. - 2013. - 6. - with. 11-12.

161. Torosjan G. G, Zholobova E.S., Rozvadovsky Island S, Mikhalev G. V, perepelova E.M.case of a chronic relapsing multifocal osteomyelin at the child of early age.//Pediatrics. - 2012. - 5. - С.155

- 158.

162. Jagudina R. I, Zinchuk I. Ju, Kulikov A. Ju. The Farmakoekonomichesky analysis of application of genno-engineering biological preparations at juvenilnom a pseudorheumatism.//Farmakoekonomika. - 2011. - 4. - С.18 - 22.